- Home
- MBBC vs NRSN Comparison
MBBC vs NRSN Comparison
Compare MBBC & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBBC
- NRSN
- Stock Information
- Founded
- MBBC 1902
- NRSN 2017
- Country
- MBBC United States
- NRSN Israel
- Employees
- MBBC N/A
- NRSN N/A
- Industry
- MBBC Banks
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MBBC Finance
- NRSN Health Care
- Exchange
- MBBC Nasdaq
- NRSN Nasdaq
- Market Cap
- MBBC 30.8M
- NRSN 29.8M
- IPO Year
- MBBC N/A
- NRSN 2021
- Fundamental
- Price
- MBBC $10.80
- NRSN $1.10
- Analyst Decision
- MBBC
- NRSN Buy
- Analyst Count
- MBBC 0
- NRSN 2
- Target Price
- MBBC N/A
- NRSN $14.00
- AVG Volume (30 Days)
- MBBC 3.6K
- NRSN 245.5K
- Earning Date
- MBBC 11-22-2025
- NRSN 12-17-2025
- Dividend Yield
- MBBC N/A
- NRSN N/A
- EPS Growth
- MBBC N/A
- NRSN N/A
- EPS
- MBBC 0.02
- NRSN N/A
- Revenue
- MBBC $6,885,334.00
- NRSN N/A
- Revenue This Year
- MBBC N/A
- NRSN N/A
- Revenue Next Year
- MBBC N/A
- NRSN N/A
- P/E Ratio
- MBBC $738.74
- NRSN N/A
- Revenue Growth
- MBBC 1.92
- NRSN N/A
- 52 Week Low
- MBBC $6.61
- NRSN $0.80
- 52 Week High
- MBBC $12.89
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- MBBC 54.79
- NRSN 36.30
- Support Level
- MBBC $10.54
- NRSN $1.15
- Resistance Level
- MBBC $11.22
- NRSN $1.30
- Average True Range (ATR)
- MBBC 0.36
- NRSN 0.07
- MACD
- MBBC -0.01
- NRSN -0.01
- Stochastic Oscillator
- MBBC 18.82
- NRSN 0.00
About MBBC Marathon Bancorp Inc. Common Stock
Marathon Bancorp Inc is a Wisconsin-chartered savings bank. It is a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the Company's revenues come from interest income on loans and debt securities.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.